Format

Send to

Choose Destination
See comment in PubMed Commons below
J Clin Endocrinol Metab. 2013 Oct;98(10):3932-8. doi: 10.1210/jc.2013-2491. Epub 2013 Aug 8.

Bloom syndrome in short children born small for gestational age: a challenging diagnosis.

Author information

1
MD, Erasmus Medical Center/Sophia Children's Hospital, Dr Molewaterplein 60, Room Sb-2603, 3015 GJ Rotterdam, The Netherlands. j.renes@erasmusmc.nl.

Abstract

BACKGROUND:

GH treatment has become a frequently applied growth-promoting therapy in short children born small for gestational age (SGA). In some disorders GH treatment is contraindicated, eg, chromosomal breakage syndromes. Bloom syndrome is a rare chromosomal breakage syndrome characterized by severe pre- and postnatal growth deficiency, a photosensitive facial erythema, immunodeficiency, mental retardation or learning disabilities, endocrinopathies, and a predisposition to develop a wide variety of cancers.

OBJECTIVE:

We report 2 patients with Bloom syndrome illustrating the variety in clinical manifestations. They were initially diagnosed with short stature after SGA birth and Silver Russell syndrome and treated with GH.

CASES:

Both patients presented with pre- and postnatal growth failure but no clear other characteristic features associated with Bloom syndrome. Photosensitive skin lesions developed only at a pubertal age and were minimal. Also, both children showed normal immunoglobulin levels, normal development, and no signs of endocrinopathies at start of GH. Dysmorphic features resembling Silver Russell syndrome were observed in both patients. Remarkably, during GH treatment IGF-1 levels increased to values greater than 3.5 SD score, with normal IGF binding protein-3 levels.

CONCLUSION:

Short children born SGA comprise a heterogeneous group. Bloom syndrome should be tested for in children with consanguineous parents, dysmorphic features (particularly resembling Silver Russell syndrome), skin abnormalities, and/or IGF-1 levels greater than 2.5 SD score during standard GH treatment with normal IGF binding protein-3 levels.

PMID:
23928670
DOI:
10.1210/jc.2013-2491
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Silverchair Information Systems
    Loading ...
    Support Center